Did you know that healthcare communication can significantly enhance different objective and subjective health outcomes, including patient satisfaction?¹⁻³ #HematologicalMalignancy care and communication involves many aspects such as breaking bad news, conveying hope, shared-decision making, addressing cross-cultural concerns, treatment side effects, and complementary/alternative medicine.³ Mastering communication skills is key to effective care.³ What is your perspective on communication in cancer care?
Lilly Oncology International
Pharmaceutical Manufacturing
Channel for the Professional Oncology & Hematology Communities. Follow us for updates.
About us
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, including transforming the most difficult-to-treat cancers into manageable diseases. Our approach centers on creating oncology medicines that unequivocally show early signs of clinical activity and will matter to patients. When you engage with Lilly Oncology International on LinkedIn (and any other of Lilly's social media channels), you are agreeing to these Community Guidelines: https://e.lilly/3XKThyc You are also agreeing to the terms and conditions, or other legal notices provided by Lilly and those of LinkedIn.
- Website
-
www.lilly.com/disease-areas/cancer
External link for Lilly Oncology International
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1,001-5,000 employees
- Headquarters
- Indianapolis
- Specialties
- Oncology and Biopharmaceuticals
Updates
-
Did you know that 70% of patients with #HematologicalMalignancy prefer treatment success rates to be communicated in multiple ways, with 88% favoring percentages? In a multicenter observational study, 216 patients with hematological malignancy provided their information preferences. The most common sources of information for patients were their physician and the internet. The results showed that information preferences vary between patients and tailoring information to match how individual patients best understand key facts about their disease and treatment can enhance communication. What are the information preferences of your patients?
-
-
Do your patients with #HematologicalMalignancy want to be actively involved in discussions and decisions about their care? Patients with hematological malignancies increasingly prefer to be involved in treatment decisions. Shared decision-making supports this by fostering collaboration in preference-sensitive choices. These decisions arise when well-informed patients weigh the pros and cons differently or when multiple treatment options, including no treatment, are equally viable. A survey of 95 patients with hematological malignancy and their physicians in the Netherlands suggests that one of the challenges in shared decision-making can be extracting information from the patient, but that focusing on preference talk can support patient engagement. How do you get patients engaged in shared decision-making? Stay informed with our Hema Pulse series.
-
#Lymphoma has a significant impact on patients’ lives and wellbeing. Despite advances in the rate of lymphoma survivors, the treatment of cancer is unfortunately not without consequence. Understanding the unmet needs of lymphoma survivors can enable informed decision‐making relating to survivorship care. Understanding the prevalence of survivors experiencing difficulties, and the nature of their unmet needs, is needed to promote recovery and supportive self‐management. What do patients with lymphoma in your clinical practice describe as their unmet needs?
-
-
How do you identify your patient’s treatment preferences? Understanding patient priorities can help inform treatment decisions in #HematologicalMalignancy. Discover the latest updates in #Hematology with our Hema Pulse series.
-
-
#ASH24 is here! Ready to explore the latest breakthroughs in #Hematology and connect with experts? Visit the Lilly booth, engage with leading professionals, and be part of the conversation. See you there!
-
-
Excited about the future of #Hematology? #ASH24, the largest and most comprehensive hematology event of the year, is almost here. Join us and prepare for days of learning and inspiration!
-
-
Risk assessment in #BreastCancer is essential for clinical decisions. The future of predicting #RiskofRecurrence relies on a personalized approach, using diverse tools to accurately gauge recurrence risk and provide tailored patient care.
-
-
Learn from Prof. Matteo Lambertini about the significance of ctDNA monitoring as a tool for predicting the #RiskOfRecurrence. Watch now and stay tuned for more updates!